DE

Preliminary Injunctions rejected in Infringement Proceedings concerning Gilead’s SPC Supplementary Protection Certificate of the anti-HIV drug Truvada in Germany

The Munich Regional Court recently rejected Gilead’s motion for preliminary injunctions based on Gilead’s Truvada SPC in first instance against seven pharmaceutical companies. The Court’s judgement relied on the qualified guidance order of the Federal Patent Court concerning the validity of the SPC in the parallel nullity proceedings (4 Ni 12/17) .

The anti-HIV drug Truvada is a fixed-dose combination of the two active ingredients tenofovir disoproxil and emtricitabine. The patent of tenofovir disoproxil (EP 0 915 894 B1) expired at the end of July. Gilead’s Truvada SPC which is based on said patent covers the combination of tenofovir disoproxil and emtricitabine and does not expire until February 2020.

Four nullity actions have been filed against the Truvada SPC with the Federal Patent Court (4 Ni 12/17). The Truvada SPC has been challenged by all claimants for not complying with Article 3(a) of Regulation (EC) 469/2009, since in the claimants’ view, the combination of tenofovir disproxil and emtricitabine is not protected by the basic patent. At the beginning of August, the Federal Patent Court issued the qualified guidance order also considering the Truvada SPC as being invalid, since the combination of tenofovir and emtricitabine lacks protection by the basic patent. The oral hearing in the case on the merits will take place before the Federal Patent Court in May of next year.

An Isenbruck Bösl Hörschler team of our partners Fritz Lahrtz and Ulrike Herr is currently representing one of the pharmaceutical companies together with an attorney-at-law from the Munich office of an international law firm. They would be happy to answer any questions you may have.

More articles from Dr. Ulrike Herr

SPCs for combination products – The CJEU sets out the criteria for combinations of active ingredients being “protected by a basic patent”

Dr. Ulrike Herr

We are pleased to announce that our Munich partner Dr. Ulrike Herr was reelected today as a member of the Board of the German Chamber of Patent Attorneys

Dr. Ulrike Herr

Preliminary Injunctions rejected in Infringement Proceedings concerning Gilead’s SPC Supplementary Protection Certificate of the anti-HIV drug Truvada in Germany

Dr. Ulrike Herr

Highly Topical: Supplementary Protection Certificates SPCs in Europe – Seattle Genetics Decision (C-471/14) of the CJEU of October 6, 2015 – Good news for SPC Owners

Dr. Ulrike Herr

Urgent Notice of the Federal Patent Court: Preliminary Injunction issued in a Compulsory License Proceedings concerning “Isentress” (raltegravir against AIDS)

Dr. Ulrike Herr

SPCs and Medical Devices: Regulation 469/2009 requires a pharmacological, immunological or metabolic action of the product of its own: BPatG Decision 14 W (pat) 45/12

Dr. Ulrike Herr

Highly Topical: SPCs Supplementary Protection Certificates in Europe – Seattle Genetics Decision (C-471/14) of the CJEU of October 6, 2015 – Good news for SPC Owners

Dr. Ulrike Herr

Reference to an ISO Standard Renders a Claim Unclear under the EPC

Dr. Ulrike Herr

The article “BPatG – Telmisartan. Zur Nichtigkeit von ergänzenden Schutzzertifikaten für Wirkstoffkombinationen” by Ulrike Herr was published in IP kompakt

Dr. Ulrike Herr

Supplementary Protection Certificates – Three post-Medeva Decisions of the CJEU of Dec 12, 2013

Dr. Ulrike Herr

SPC Case Law - Astrazeneca AB/Comptroller-General of Patents C-617/12 of Nov. 14, 2013 (Reasoned order)

Dr. Ulrike Herr